论我国再生医学法律问题及其规制  

Discussion on the Legal Problems of Regenerative Medicine and Its Regulation in China

作　　者：叶子云 肖燕平[2] YE Zi-yun;XIAO Yan-ping(School of Marxism,Gannan Medical University,Ganzhou 341000,China)

机构地区：[1]赣南医学院马克思主义学院,江西赣州341000 [2]赣南医学院第一附属医院康复医学科,江西赣州341000

出　　处：《医学与哲学》2021年第9期66-70,共5页Medicine and Philosophy

基　　金：2019年赣南医学院校级科研课题一般项目(YB201955);2020年江西省高校人文社会科学青年项目(FX20214);2021年赣州市社会科学研究一般课题(2021-018-0012)。

摘　　要：再生医学通过技术手段重塑损害部位或重塑器官达到救治疾病或者以人类需求为期望提升生活质量,其巨大的发展潜力以及背后带来的巨大的经济利益,使其成为世界各国竞相布局的国家战略。我国《民法典》首次在立法层面规定了再生医学中基因和胚胎的科研底线问题,相关国家规划也对再生医学内容做了重要战略部署,然而我国再生医学领域发展存在相关的法规政策滞后、缺乏有效的风险监管机制等问题,阻碍了再生医学为代表的创新医疗技术的发展。所以,亟待建立完备的再生医学法律体系,为构建我国再生医学立法起到启示和参考作用。Regenerative medicine can cure diseases or improve the quality of life by reshaping damaged parts or organs through technical means.The huge development potential and economic benefits behind it make it a national strategy for countries all over the world.The"civil code"of China sets in regenerative medicine research on genetic and embryonic bottom line problem at the legislative level for the first time,relevant national planning also has made the important strategic deployment of regenerative medicine content.However,there are some problems of the development of regenerative medicine,such as regulations and policies lag,effective risk supervision mechanism deficit,etc.,which hinder the innovation of regenerative medicine represented the development of medical technology.Therefore,it is urgent to establish a complete legal system of regenerative medicine to inspire and construct the legislation of regenerative medicine in China.

关 键 词：再生医学 临床医学 法律制度 风险监管 

分 类 号：R-05[医药卫生]